CELEX: 62016TA0803
Language: en
Date: 2018-06-06 00:00:00
Title: Case T-803/16: Judgment of the General Court of 6 June 2018 — Glaxo Group v EUIPO — Celon Pharma (SALMEX) (EU trade mark — Invalidity proceedings — EU figurative mark SALMEX — Earlier three-dimensional national mark — Competence of the Board of Appeal to examine of its own motion whether the earlier mark had been put to genuine use — Article 64(1) and Article 76(1) of Regulation (EC) No 207/2009 (now Article 71(1) and Article 95(1) of Regulation (EU) 2017/1001))

201806290581986302018/C 249/318032016TC24920180716EN01ENINFO_JUDICIAL20180606252622Case T-803/16: Judgment of the General Court of 6 June 2018 — Glaxo Group v EUIPO — Celon Pharma (SALMEX) (EU trade mark — Invalidity proceedings — EU figurative mark SALMEX — Earlier three-dimensional national mark — Competence of the Board of Appeal to examine of its own motion whether the earlier mark had been put to genuine use — Article 64(1) and Article 76(1) of Regulation (EC) No 207/2009 (now Article 71(1) and Article 95(1) of Regulation (EU) 2017/1001))
 ---documentbreak--- C2492018EN2520120180606EN0031252262Judgment of the General Court of 6 June 2018 — Glaxo Group v EUIPO — Celon Pharma (SALMEX)
   (Case T-803/16) (
         1
      )
   ‛(EU trade mark — Invalidity proceedings — EU figurative mark SALMEX — Earlier three-dimensional national mark — Competence of the Board of Appeal to examine of its own motion whether the earlier mark had been put to genuine use — Article 64(1) and Article 76(1) of Regulation (EC) No 207/2009 (now Article 71(1) and Article 95(1) of Regulation (EU) 2017/1001))’2018/C 249/31Language of the case: English
      Parties
   
   
      Applicant: Glaxo Group Ltd (Brentford, United Kingdom) (represented by: S. Baran, T. St Quintin, S. Wickenden, Barristers, E. Morris and R. Jacob, Solicitors)
   
      Defendant: European Union Intellectual Property Office (represented by: D. Hanf, acting as Agent)
   
      Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Celon Pharma S.A. (Łomianki, Poland) (represented by: M. Krasiński, lawyer)
   
      Re:
   
   Action brought against the decision of the Fourth Board of Appeal of EUIPO of 31 August 2016 (Case R 2108/2015-4) relating to invalidity proceedings between Glaxo Group Ltd and Celon Pharma.
   
      Operative part of the judgment
   
   The Court:
   
            1.
         
         
            Annuls the decision of the Fourth Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 31 August 2016 (Case R 2108/2015-4);
         
      
            2.
         
         
            Orders EUIPO to bear its own costs and those incurred by Glaxo Group Ltd during the proceedings before the General Court;
         
      
            3.
         
         
            Orders Celon Pharma S.A. to bear its own costs relating to the proceedings before the General Court.
         
      (
         1
      )	OJ C 22, 23.1.2017.